大麻效力，定義為 Δ⁹-四氫大麻酚 (THC) 的濃度，在國際上有所增加，這可能會增加大麻使用者出現不良健康後果的風險。我們提出了第一個大麻效力與心理健康和成癮關係的系統評論（PROSPERO，CRD42021226447）。 我們搜索了 Embase、PsycINFO 和 MEDLINE（從資料庫設立到 2021 年 1 月 14 日）。納入觀察性研究，比較了高效能大麻（THC 濃度較高的產品）和低效大麻（THC 濃度較低的產品）THC 的濃度），如納入的研究所定義，伴有抑鬱、焦慮、精神疾病或使用大麻障礙（cannabis use disorder, CUD）。 總體而言，相對於較低效力的大麻，使用較高效力的大麻，與精神疾病和使用大麻障礙的風險增加有關。
Association of cannabis potency with mental ill health and addiction: a systematic review
Kat Petrilli, Shelan Ofori, Lindsey Hines, Gemma Taylor, Sally Adams, Tom P Freeman
Cannabis potency, defined as the concentration of Δ⁹-tetrahydrocannabinol (THC), has increased internationally, which could increase the risk of adverse health outcomes for cannabis users. We present, to our knowledge, the first systematic review of the association of cannabis potency with mental health and addiction (PROSPERO, CRD42021226447). We searched Embase, PsycINFO, and MEDLINE (from database inception to Jan 14, 2021). Included studies were observational studies of human participants comparing the association of high-potency cannabis (products with a higher concentration of THC) and low-potency cannabis (products with a lower concentration of THC), as defined by the studies included, with depression, anxiety, psychosis, or cannabis use disorder (CUD). Of 4171 articles screened, 20 met the eligibility criteria: eight studies focused on psychosis, eight on anxiety, seven on depression, and six on CUD. Overall, use of higher potency cannabis, relative to lower potency cannabis, was associated with an increased risk of psychosis and CUD. Evidence varied for depression and anxiety. The association of cannabis potency with CUD and psychosis highlights its relevance in health-care settings, and for public health guidelines and policies on cannabis sales. Standardisation of exposure measures and longitudinal designs are needed to strengthen the evidence of this association.
Lancet Psychiatry 2022; 9: 736–50
https://doi.org/10.1016/S2215-0366(22)00161-4
